Candel leads biotech gainers amid wave of data readouts

Amid a busy period for clinical readouts, Candel led gainers on the market among biopharmas posting data since the stock market closed on Tuesday. 

Shares in President and CEO Paul Peter Tak’s biotech,  Candel Therapeutics Inc. (NASDAQ:CADL), rose $3.14 to $7.75 for a 68% gain and a closing market cap north of $250 million on the back of positive top-line data for CAN-2409 in intermediate-to-high risk localized prostate cancer. Candel plans to speak with FDA about the regulatory path forward...